



Draig Therapeutics to Participate in the Stifel 2026 Virtual CNS Forum

March 12, 2026 (NEWTON, MA, USA) - Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies, announced today that Ivana Magovčević-Liebisch, President and Chief Executive Officer, and Simon Ward, Chief Scientific Officer and Founder, will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum.

The session will be held on Tuesday, March 17, 2026, from 12:30-12:55 PM Eastern (USA). To access the live webcast, please visit [this link](#).

About Draig Therapeutics

Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies. Our pipeline of highly specific AMPA receptor and GABA_A receptor modulators are designed to enable safe, precise modulation of the major neurocircuits underlying neuropsychiatric disorders. Our lead program, DT-101, is a Phase 2 AMPA receptor positive allosteric modulator (AMPA-PAM) with best-in-disease potential in major depressive disorder. Working in partnership with patients and their care partners, Draig is transforming the future of neuropsychiatry.